01738nas a2200385   4500000000100000008004100001260001600042653001500058653001000073653001600083653002300099653001000122653002100132653001100153653001100164653002600175653001200201653000900213653001800222653001500240653001700255653002600272653001200298100001400310700001100324700001300335700001400348700001700362700001700379245008600396300001100482490000700493520083800500022001401338       2001                            d  c2001 May 1410aAdolescent10aAdult10aBCG Vaccine10aBacterial Vaccines10aChild10aChild, Preschool10aFemale10aHumans10aImmunization Schedule10aleprosy10aMale10aMycobacterium10aSkin Tests10aTime Factors10aVaccines, Inactivated10aVietnam1 aTruoc L V1 aLy H M1 aThuy N K1 aTrach D D1 aStanford C A1 aStanford J L00aVaccination against leprosy at Ben San Leprosy Centre, Ho Chi Minh City, Vietnam.  a3451-80 v193 a<p>Three vaccines, BCG alone, BCG + 10(7) killed Mycobacterium vaccae and 10(8) killed M. vaccae alone, were studied in children living in close contact with leprosy. In the year before vaccination, 14/446 (3.1%) children had developed leprosy. Among those who were not vaccinated, 9/74 (12.2%) developed the disease in the first 4 years of the study and 5/65 (7.7%) developed the disease in the second 4 years. In comparison with this, among those vaccinated, 20/343 (5.8%) developed leprosy in the first 4 years and 5/323 (1.5%) developed leprosy in the second 4 years. This represents 52.5% protection in the first 4 years and 80.5% in the second 4 years. There were no significant differences in protection afforded by each of the three vaccines but the success of the killed preparation of M. vaccae is an important finding.</p>  a0264-410X